Walleye Capital LLC Buys 127,800 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Walleye Capital LLC boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 955.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 141,171 shares of the company's stock after buying an additional 127,800 shares during the period. Walleye Capital LLC owned approximately 0.16% of IDEAYA Biosciences worth $4,472,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Allworth Financial LP lifted its stake in IDEAYA Biosciences by 800.0% in the third quarter. Allworth Financial LP now owns 900 shares of the company's stock valued at $29,000 after buying an additional 800 shares during the last quarter. Covestor Ltd grew its stake in IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after acquiring an additional 922 shares in the last quarter. Quest Partners LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $41,000. US Bancorp DE lifted its holdings in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Comerica Bank boosted its position in shares of IDEAYA Biosciences by 723.5% in the first quarter. Comerica Bank now owns 1,507 shares of the company's stock valued at $66,000 after acquiring an additional 1,324 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on IDYA shares. Leerink Partners lowered IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Oppenheimer reaffirmed an "outperform" rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. JPMorgan Chase & Co. decreased their target price on IDEAYA Biosciences from $69.00 to $66.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Stephens started coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They set an "overweight" rating and a $51.00 target price for the company. Finally, Citigroup lowered their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 27th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.67.

IDEAYA Biosciences Trading Up 0.3 %

NASDAQ:IDYA traded up $0.09 during midday trading on Monday, hitting $27.45. 627,452 shares of the company were exchanged, compared to its average volume of 869,627. The company has a fifty day simple moving average of $29.53 and a 200 day simple moving average of $35.23. IDEAYA Biosciences, Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $47.74. The company has a market capitalization of $2.37 billion, a PE ratio of -11.78 and a beta of 0.86.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03. During the same quarter last year, the firm posted ($0.46) EPS. As a group, equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.